Stephen Christopher, Touil Leila, Vaiude Partha, Singh Jaipaul, McKirdy Stuart
a Department of Plastic Surgery , Royal Preston Hospital , Preston , UK.
b School of Forensic & Applied Sciences, University of Central Lancashire , Preston , UK.
J Plast Surg Hand Surg. 2018 Feb;52(1):37-39. doi: 10.1080/2000656X.2017.1319846. Epub 2017 May 9.
Attempts at the pharmacological treatment of Dupuytren's disease have so far been unsuccessful, and the disease is not yet fully understood on a cellular level. The Renin-Angiotensin System has long been understood to play a circulating hormonal role. However, there is much evidence showing Angiotensin II to play a local role in wound healing and fibrosis, with ACE inhibitors being widely used as an anti-fibrotic agent in renal and cardiac disease.
This study was designed to investigate the presence of Angiotensin II receptors 1 (AT1) and 2 (AT2) in Dupuytren's tissue to form a basis for further study into the pharmacological treatment of this condition. Tissue was harvested from 11 patients undergoing surgery for Dupuytren's disease. Each specimen was processed into frozen sections and immunostaining was employed to identify AT1 and AT2 receptors.
Immunostaining for AT1 receptors was mildly positive in one patient and negative in all the remaining patients. However, all specimens stained extensively for AT2 receptors. This suggests that the expression of AT2 receptors is more prominent than AT1 receptors in Dupuytren's disease.
These findings have opened a new avenue for future research involving ACE inhibitors, AT2 agonists, and AT2 antagonists in Dupuytren's disease.
迄今为止，针对掌腱膜挛缩症的药物治疗尝试均未成功，而且在细胞水平上对该疾病仍未完全了解。长期以来，肾素 - 血管紧张素系统一直被认为发挥着循环激素的作用。然而，有大量证据表明血管紧张素II在伤口愈合和纤维化中发挥局部作用，血管紧张素转换酶抑制剂在肾脏和心脏疾病中被广泛用作抗纤维化药物。
本研究旨在调查掌腱膜挛缩症组织中血管紧张素II受体1（AT1）和2（AT2）的存在情况，为进一步研究该病症的药物治疗奠定基础。从11例接受掌腱膜挛缩症手术的患者身上采集组织。每个标本被制成冰冻切片，并采用免疫染色来识别AT1和AT2受体。
AT1受体的免疫染色在1例患者中呈弱阳性，在其余所有患者中均为阴性。然而，所有标本中AT2受体均呈广泛染色。这表明在掌腱膜挛缩症中，AT2受体的表达比AT1受体更为显著。
这些发现为未来在掌腱膜挛缩症中涉及血管紧张素转换酶抑制剂、AT2激动剂和AT2拮抗剂的研究开辟了一条新途径。
